MetaCap

MindWalk (HYFT) vs NextCure (NXTC)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

NextCure (NXTC) has outperformed MindWalk (HYFT) over the past year, losing 38.6% versus a loss of 59.0%. Over five years, HYFT leads with a -89.3% price change compared with -91.1% for NXTC. MindWalk is the larger company by market cap ($32.6 million vs $29.5 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

HYFT-59.02%NXTC-38.63%
+74%-9%-92%
Nov 21, 20251 yearNov 20, 2026
HYFT-87.65%NXTC-90.73%
+22%-41%-103%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

HYFT versus NXTC key metrics
MetricHYFTNXTC
Share price$0.6844$6.45
Market cap$32.56M$29.53M
1-day change-14.27%-4.87%
YTD return-62.40%-54.55%
1-year return-59.02%-38.63%
5-year return-89.34%-91.07%
EPS (TTM)$-0.26$-6.78
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)—$-55.84M
52-week high$2.99$15.74
52-week low$0.64$1.55
Distance from 52-week high-77.11%-59.02%
Analyst consensusnonenone
Avg. price target upside+532.67%+210.08%
Average volume257.86K79.46K
Shares outstanding47.57M4.58M
Employees7440
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • NXTC has outperformed HYFT by 20.4 percentage points over the past year.

About MindWalk

HYFT stock →

MindWalk Holdings Corp. operates as a bio-native AI company.

Health Care · Biotechnology: Pharmaceutical Preparations · 74 employees

About NextCure

NXTC stock →

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors.

Health Care · Biotechnology: Pharmaceutical Preparations · 40 employees

HYFT vs NXTC FAQ

Which is bigger, MindWalk or NextCure?

MindWalk (HYFT) is larger, with a market capitalization of $32.56M compared with $29.53M for NextCure (NXTC).

Which stock has performed better over the past year, HYFT or NXTC?

NXTC returned -38.63% over the past 12 months, compared with -59.02% for HYFT (price return, excluding dividends). Past performance does not predict future results.

Are MindWalk and NextCure in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons